TD-6450 clinical trials
Also written TD-6450.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses TD-6450 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TD-6450
- 4
Studies by the year they started
4 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Theravance Biopharma (2) · Trek Therapeutics, PBC (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses TD-6450 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- TD-6450 MAD Study in HCV Infected SubjectsCompletedPhase 1Theravance BiopharmaNCT02116543Written as TD-6450How we know
- TD-6450 SAD and MAD in Healthy SubjectsCompletedPhase 1Theravance BiopharmaNCT02022306Written as TD-6450How we know
- A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus InfectionCompletedPhase 2Trek Therapeutics, PBCNCT02716428Written as TD-6450How we know
- A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionCompletedPhase 2Trek Therapeutics, PBCNCT02593162Written as TD-6450How we know